<DOC>
	<DOCNO>NCT00463450</DOCNO>
	<brief_summary>The typical menopausal symptom associate variety physical psychological change ( e.g . nervousness , anxiety , depression ) also impaired sexual interest enjoyment cause lack estrogen , female sex hormone produce inside body . To treat symptom , woman postmenopausal receive therapy call 'hormone replacement therapy ' ( dosage hormone replace body 's deficient hormone ) , instance , estrogen preparation inject muscle.In woman uterus estrogen use cause line womb ( endometrium ) grow ( thicken ) menopause . With long-term use may lead pathological change endometrium . That therapy complement estrogen ' natural counterbalance , progesterone ( progestogen ) , certain interval . This cause line womb shed , monthly bleed like normal period , thus avoid excessive endometrial growth.Estrogen treatment well know relieve psychological complaint . The combination estrogen weak androgen ( case Dehydroepiandrosterone ( DHEA ) ) presume clearly increase effect . The present clinical study prove Gynodian ? Depot combination estrogen androgen well effect psychological complaint sexuality postmenopausal woman treatment estrogen Estradiol valerate alone.All patient receive therapy , differ sequence . Either receive Gynodian ? Depot first five cycle estrogen-only preparation cycle 6-10 ( treatment group 1 ) receive study medication reverse order ( treatment group 2 ) . Patients assign one two group random . In either case give injection gluteal muscle every four weeks.Women intact uterus , addition injection ( day injection 1st day cycle ) take tablet contain 5 mg Medroxyprogesterone acetate ( MPA ) ( progestogen ) per day 14 day ( cycle day 15-28 ) enable endometrium shed monthly period.The study extend total period 11 month , patient 16 appointment examinations.After patient sign informed consent form participation clinical study , investigator ask , diseases moment past 12 month medicinal product take . Subsequently , gynecological examination ( include breast ) well general physical examination . Blood pressure , heart rate well body height weight measure note . In addition , doctor question physical psychological menopausal complaint mean two different , short questionnaire . Only evaluation two questionnaire show eligible participation clinical study , follow action carry through.Approx . 40 ml blood take patient thorough laboratory test include hormone level , ask urine sample . Additionally , vaginal ultrasound examination womb lining , cervical smear test ( unless already do last three month ) , x-ray examination breast ( mammography ) ( unless already do last 12 month ) .These measure repeat Final visit.About 3 week visit 1 , investigator result test prescribe visit 1 , patient ask appear visit 2.If patient eligible participation clinical study , give first injection study medication.During follow visit , injection give , blood pressure pulse rate well body weight measure blood drawn measure hormone levels.All procedure apply also second treatment period . When switch second treatment period physical gynecological examination additionally performed.Questionnaires filled patient different time point study .</brief_summary>
	<brief_title>Efficacy GynodianÂ® Depot Women With Impaired Well-being</brief_title>
	<detailed_description>The study previously post Schering AG , Germany . Schering AG , Germany rename Bayer Schering Pharma AG , Germany.Bayer Schering Pharma AG , Germany sponsor trial .</detailed_description>
	<mesh_term>Medroxyprogesterone Acetate</mesh_term>
	<criteria>Written inform consent Postmenopausal status ( amenorrhea least 12 month ) 45 65 year age Application estrogen cyclic estrogen/progestin preparation study medication least 6 month prior Visit 1 Relevant impairment wellbeing mood inspite estrogen therapy ( confirmed questionnaire score ) BMI &lt; 33kg/m2 Uterine bleed unknown etiology within last 2 year Previous exist suspect carcinoma breast Any malignant disease last 5 year Endometrial double layer thickness &gt; 5 mm History thromboembolic event exist thromboembolic process Prior hormone replacement therapy androgens within 12 month prior Visit 1 Major life event within last 12 month prior Visit 1</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Hormone Replacement Therapy</keyword>
	<keyword>Impaired well-being , mood sexuality</keyword>
</DOC>